← Back to Search

Non-invasive Brain Stimulation

Brain Stimulation for Schizophrenia

N/A
Recruiting
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All subjects must have the ability to give valid informed consent
Stable outpatient or partial hospital status
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessment begins with the initial baseline interview and concludes after a 2-week follow-up assessment using the same clinical measures.
Awards & highlights

Study Summary

This trial will test if a non-invasive brain stimulation can help reduce symptoms in people with schizophrenia.

Who is the study for?
This trial is for English-speaking adults with a stable mental health status and normal IQ, diagnosed with schizophrenia or related disorders. It's not for those under 18, with recent substance abuse, metal implants, skin conditions at electrode sites, head trauma, epilepsy, severe psychiatric disorders other than schizophrenia spectrum disorders, heart devices like pacemakers or defibrillators, certain hairstyles that interfere with equipment placement on the head.Check my eligibility
What is being tested?
The study tests if transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique can reduce auditory hallucinations and negative symptoms in people with schizophrenia. Participants' clinical symptoms and cognitive abilities will be measured to see if tDCS has beneficial effects.See study design
What are the potential side effects?
Potential side effects of tDCS may include discomfort at the electrode site on the scalp such as itching or tingling during application; headache; fatigue; nausea; and insomnia. These are generally mild and temporary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can understand and agree to the study's details on my own.
Select...
I am not fully hospitalized and can manage some daily activities.
Select...
I am 18 years old or older.
Select...
I have been diagnosed with schizophrenia or a related disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessment begins with the initial baseline interview and concludes after a 2-week follow-up assessment using the same clinical measures.
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessment begins with the initial baseline interview and concludes after a 2-week follow-up assessment using the same clinical measures. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Symptom Severity of Auditory Hallucinations
Change in Symptom Severity of Negative Symptoms

Side effects data

From 2021 Phase 2 & 3 trial • 160 Patients • NCT02483468
2%
skin irritation
2%
Car accident
100%
80%
60%
40%
20%
0%
Study treatment Arm
tDCS (Active)
tDCS (Sham)

Trial Design

1Treatment groups
Experimental Treatment
Group I: dlPFC/TPJ Stimulation + RestExperimental Treatment1 Intervention
20 minutes of 2 mA direct current stimulation during rest.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Direct Current Stimulation
2014
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
909 Previous Clinical Trials
4,704,115 Total Patients Enrolled
3 Trials studying Schizophrenia
286 Patients Enrolled for Schizophrenia

Media Library

Transcranial Direct Current Stimulation (Non-invasive Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05053451 — N/A
Schizophrenia Research Study Groups: dlPFC/TPJ Stimulation + Rest
Schizophrenia Clinical Trial 2023: Transcranial Direct Current Stimulation Highlights & Side Effects. Trial Name: NCT05053451 — N/A
Transcranial Direct Current Stimulation (Non-invasive Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05053451 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this investigation allow for participation of seniors aged 75 or above?

"The cut-off for participation in this trial is 65 years old, so it does not include minors. However, there are 46 clinical trials available to patients who fall below 18 and 164 that cater to those over the age of 65."

Answered by AI

Is it possible for me to participate in this clinical experiment?

"Participants for this study are limited to 15 adults, between the age of 18 and 65, who have been diagnosed with schizophrenia. Additionally, all potential enrollees must be over 18 years old and possess a relatively stable mental health status as outpatient or partial hospital patients."

Answered by AI

Is the recruitment of participants ongoing for this investigation?

"This clinical research is actively recruiting patients, with data hosted on the official website indicting that it was posted initially on September 14th 2021 and revised most recently on November 22nd 2021."

Answered by AI

What is the patient enrollment quota for this clinical investigation?

"Affirmative, the information hosted on clinicaltrials.gov verifies that this medical study is actively searching for participants. The trial was first listed on September 14th 2021 and most recently updated on November 22nd 2021. A total of 15 patients must be recruited from one location."

Answered by AI

Who else is applying?

What state do they live in?
Illinois
What site did they apply to?
Imaging Research Center
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
2

How responsive is this trial?

Average response time
  • < 1 Day
Most responsive sites:
  1. Imaging Research Center: < 24 hours
Typically responds via
Email
~4 spots leftby Mar 2025